1999•Breast CancerRequires access

Prospective randomized study of cyclophosphamide, epirubicin, and 5-fluorouracil versus cyclophosphamide, adriamycin, and 5-fluorouracil in advanced or recurrent breast cancer

Tetsuro Kobayashi, Hiroki Koyama, Takahiro Oka, Tadaki Yasumura, Norimichi Kan, Yuichi Takatsuka, Masakuni Noguchi, Ken Morimoto, Takaichiro Suzuki, Takayoshi Tobe, Takesada Mori

Open publisher page 1 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Medicine, Epirubicin, Fluorouracil, Regimen, Cyclophosphamide, Internal medicine, Leukopenia, Gastroenterology

Related papers

Back to paper searchBrowse research topicsOriginal source
Prospective randomized study of cyclophosphamide, epirubicin, and 5-fluorouracil versus cyclophosphamide, adriamycin, and 5-fluorouracil in advanced or recurrent breast cancer — Research Paper | ScholarLens